NHI.no
Annonse
Informasjon

Barneleddgikt - angrep av mange ledd

Barneleddgikt deles inn i tre hovedformer, fåledd-, flerledd eller systemisk type. Den nest vanligste typen er den der flere enn fem ledd er angrepet av sykdommen, den såkalte flerledds- eller polyartikulære typen.

Det er ikke kjent hva som er årsaken til barneleddgikt.

Sist oppdatert:

2. feb. 2022

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Barneleddgikt . Referanselisten for dette dokumentet vises nedenfor

  1. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-2. PMID: 14760812 PubMed
  2. Clinch J. Juvenile idiopathic arthritis. BMJ Best Practice, last reviewed 2 Jan 2022. bestpractice.bmj.com
  3. Songstad NT, Tylleskär K, Rygg M. Juvenil idiopatisk artritt - JIA. Generell veileder i pediatri. Norsk barnelgeforening. Revidert 2009.-
  4. Horton DB, Scott FI, Haynes K, et al. Antibiotic Exposure and Juvenile Idiopathic Arthritis: A Case–Control Study. Pedatrics 2015. doi:10.1542/peds.2015-0036 DOI
  5. Saurenmann RK, Levin AV, Feldman BM, et al. Prevalence, risk factors, and outcome of uveitis in juvenile idiopathic arthritis: a long-term followup study. Arthritis Rheum 2007; 56:647. PubMed
  6. Takken T, van der Net JJ, Helders PPJM. Methotrexate for treating juvenile idiopathic arthritis. Cochrane Database of Systematic Reviews 2001, Issue 4. Art. No.: CD003129. DOI: 10.1002/14651858.CD003129. DOI
  7. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial. JAMA 2010; 303: 1266-73. Journal of the American Medical Association
  8. Lovell DJ, Ruperto N, Goodman S et al. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 810-20. New England Journal of Medicine
  9. Lovell DJ, Reiff A, Ilowite NT, et al. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-504. pmid:18438876 PubMed
  10. Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis. Expert Opin Biol Ther. 2020;20(7):725-740. PubMed
  11. Ilowite N, Porras O, Reiff A, et al. Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study. Clin Rheumatol 2009; 28: 129-37. pmid:18766426 PubMed
  12. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013; 72: 583-9. pmid:23144446 PubMed
  13. Ruperto N, Lovell DJ, Li T, et al. Abatacept improves health-related quality of life, pain, sleep quality, and daily participation in subjects with juvenile idiopathic arthritis. Arthritis Care Res (Hobroken) 2010; 62: 1541-51. pmid:20597110 PubMed
  14. M F Silva J, Ladomenou F, Carpenter B, et al. Allogeneic hematopoietic stem cell transplantation for severe, refractory juvenile idiopathic arthritis. Blood Adv. 2018;2(7):777-786. PubMed
  15. Guzman J, Oen K, Tucker LB, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2014. doi: 10.1136/annrheumdis-2014-205372 DOI
  16. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007; 369: 767-78. pmid:17336654 PubMed
  17. Wallace CA, Giannini EH, Spalding SJ, et al. Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors. J Rheumatol 2014; 41: 1163-70. pmid:24786928 PubMed
Annonse
Annonse